tiprankstipranks

Connect Biopharma presents data on rademikibart at EAACI

Connect Biopharma (CNTB) Holdings announced the presentation of clinical data supporting rademikibart, the Company’s investigational, next-generation, potentially best-in-class anti-interleukin-4-receptor alpha antibody, at the European Academy of Allergy and Clinical Immunology, EAACI, 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually. Rademikibart significantly improved lung function and asthma control in patients with eosinophilic-driven type 2 asthma; Rademikibart reduced annualized exacerbations in patients with eosinophilic-driven type 2 asthma; Data supports ongoing Phase 2 acute exacerbation studies in asthma and COPD; expect to report topline data from both studies in 1H26

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1